Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee. The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

View post:
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

BURR RIDGE, Ill., March 07, 2024 (GLOBE NEWSWIRE) -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ Experience, is exhibiting at the American Academy of Dermatology (AAD) annual meeting in San Diego March 8-12, and unveiling a groundbreaking new technology for the noninvasive treatment of common skin cancers.

View original post here:
SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555

Ultimovacs ASA: Mandatory notification of trade by primary insiders

Oslo, 7 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, has today sold 596,006 shares in the company at an average price of NOK 9.5245 per share. Following these transactions, Langøya Invest AS and closely related parties hold 800,000 shares in Ultimovacs ASA.

Visit link:
Ultimovacs ASA: Mandatory notification of trade by primary insiders

Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions

FREMONT, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has opened a new 50,000-square-foot facility in Wuxi, China. This strategic move increases the company's manufacturing capacity to meet the growing worldwide demand for comprehensive cell analysis solutions.

View original post here:
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications (Apogee or the Company), today announced the pricing of its upsized previously announced underwritten public offering of 6,774,193 shares of common stock at a public offering price per share of $62.00. The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on March 12, 2024, subject to the satisfaction of customary closing conditions. In addition, Apogee has granted the underwriters a 30-day option to purchase up to an additional 1,016,128 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Apogee.

More here:
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

Scorpius Holdings, Inc. Announces Pricing of Public Offering

DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for aggregate gross proceeds of $1,500,000, before deducting underwriting discounts, commissions and offering expenses. All of the shares of common stock were offered by the Company. The offering is expected to close on March 12, 2024, subject to satisfaction of customary closing conditions.

See the article here:
Scorpius Holdings, Inc. Announces Pricing of Public Offering

Hyloris to Report 2023 Full-Year Results on 14 March 2024

Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will release its full year 2023 fiscal results on Thursday, 14 March 2024, at 07.00 AM CET.

View post:
Hyloris to Report 2023 Full-Year Results on 14 March 2024

Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs – Yahoo News Canada

Scientists have created miniorgans from cells floating in the fluid that surrounds a fetus in the womb an advance they believe could open up new areas of prenatal medicine.

Miniorgans, or organoids, are tiny simplified structures that can be used to test new medical treatments or study how the real organs they mimic work, whether they are healthy or diseased.

Researchers from University College London and Great Ormond Street Hospital in the United Kingdom collected cells from amniotic fluid samples taken during 12 pregnancies as part of routine prenatal testing. Then, for the first time, they grew mini-organs from cells taken during active pregnancies. They envision their approach could eventually help doctors monitor and treat congenital conditions before birth and develop personalized therapies for a baby in the womb.

Were really excited about that possibility, said Mattia Gerli of University College London, an author of the study published Monday in the journal Nature Medicine.

The tissue-specific stem cells Gerli and his colleagues collected were shed by the fetus, as normally happens during pregnancy. The scientists identified which tissues the stem cells came from, and found cells from the lungs, kidneys and intestines.

Previously, mini-organs have been derived from adult stem cells, which more closely resemble adult tissue, or fetal tissue after an abortion.

Collecting cells from amniotic fluid gets around regulations about taking stem cells directly from fetal tissue, allowing these scientists to get cells from fetuses into the latter part of pregnancy. In the U.K., the legal limit for terminating a pregnancy is generally 22 weeks after conception. Scientists cant get fetal samples after that, limiting their ability to study normal human development or congenital diseases past that point.

In the U.S., abortion restrictions vary by state. Its legal in most to use fetal tissue for research, said Alta Charo, an emeritus professor of law and bioethics at the University of Wisconsin at Madison. Fetal tissue is defined by the National Institutes of Health as coming from a dead human embryo or fetus after a miscarriage, abortion or stillbirth and the use of tissue from an abortion has long been controversial.

Story continues

Charo, who wasn't involved in the study, said the new approach doesnt raise the same ethical issues. Obtaining cells from amniotic fluid that is already being sampled for standard clinical purposes does not appear to add any physical risks to either fetus or pregnant woman, she said in an email.

Dr. Arnold Kriegstein, who directs the Developmental and Stem Cell Biology Program at the University of California, San Francisco, and also wasn't involved in the research, said getting cells this way has the potential of giving you some information about that individual fetus as its growing.

And since growing mini-organs from cells in amniotic fluid takes about 4 to 6 weeks, Gerli said, there's enough time for prenatal therapy to fix problems doctors might find.

To examine one practical use of their approach, the U.K. team worked with colleagues in Belgium to study the development of babies with a condition called a congenital diaphragmatic hernia, in which organs such as the liver and intestines get displaced into the chest because of a hole in the diaphragm. The lungs dont develop the way they should, and about 30% of fetuses with the condition die. If doctors detect the hernia, they can operate on the fetus while it's still in the womb.

Researchers grew lung organoids from the cells of fetuses with the condition before and after treatment and compared them to organoids from healthy fetuses. Dr. Paolo de Coppi, an author of the study from University College London and Great Ormond Street Hospital, said they were able to assess the affected child's condition before birth using this method. Doctors are now unable to tell families much about the outcome of a prenatal diagnosis because each case is different, he said. The ability to study functioning prenatal miniorgans, he added, is the first step toward a more detailed prognosis and more effective treatments.

Kriegstein said more research is needed. Its in the very early stages," he added, "and well have to wait and see how useful itll be in the long run.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Science and Educational Media Group. The AP is solely responsible for all content.

Laura Ungar, The Associated Press

Originally posted here:
Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada